Dermatology

In a national study of 55 million children and teens across the U.S., there were 1,240 confirmed cases of hidradenitis suppurativa (HS). Nearly all were aged 10 or older.

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer. While most cases are treatable, a small number can become serious and spread, leading to worse outcomes.

As researchers continue to explore more effective solutions, combining platelet-rich plasma (PRP) with fractional laser therapy has gained increasing attention.

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug semaglutide and allodynia, a painful skin sensitivity.

A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.

A study found that while patients with atopic dermatitis often turn to social media for skincare advice, their decisions are most influenced by healthcare professionals, personal experience, and disease severity.

Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.

In a recent discussion with Managed Healthcare Executive, three leading dermatologists and itch experts—Shawn Kwatra, M.D., Brian Kim, M.D., and Gil Yosipovitch, M.D.—shared where the science is going, what’s holding it back and how the healthcare system can better support patients.

A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how treatment options are improving and the challenges patients face in getting access to the right therapies.

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.

A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an open-label study.

A protein called NF-kB c-Rel has been found to intensify the symptoms of psoriasis, offering a potential new target for treatments.

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S. that helps restore skin color for this condition. It’s also approved to treat mild to moderate atopic dermatitis in patients 12 and older who are not immunocompromised.

Pemphigus is a rare autoimmune disease that causes painful blisters on the skin and mucous membranes, including the mouth, nose, throat, eyes and genitals.

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch without the limitations of traditional treatments.

In a phase 2 clinical trial, researchers examined baricitinib and NB-UVB in adults with severe vitiligo in the dermatology departments at 4 hospitals in France between July 2021 and April 2023.

A South Korean study explored the link between lifestyle decisions beginning in infancy and persistent atopic dermatitis, citing exclusive breast milk diet and childhood obesity as potential factors.

Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD.

Regenerative medicine focuses on repairing damaged skin and bringing back melanocytes, the cells that give skin its color.

A new study finds that that eczema can worsen when air quality drops from good to moderate levels on the Environmental Protection Agency’s Air Quality Index.

Researchers reviewed 900 Reddit posts to assess opinions about the increasingly popular class of drugs.

The campaign for hand eczema is the latest in a number of high-cost campaigns to raise awareness of dermatological conditions.

Repigmentation case is just the third that has been reported.

Ebglyss also provided meaningful improvements in difficult-to-treat face and hand dermatitis.

Research shows that after 60 months of treatment, 38% of patients achieved complete remission.

Mental health and vitiligo treatment outcomes may be associated because of a brain-skin axis, a pathway that links emotional stress to skin conditions.

Previous research has shown an association between atopic dermatitis and obesity. But these findings elaborate on that observation and point to a connection to abnormal lipid metabolism and elevated "bad" LDL cholesterol levels.

This is the first study to investigate the effectiveness of this combination to treat vitiligo.